Atrial Fibrillation Drugs Market To Witness Significant Growth By 2027

The atrial fibrillation drugs market is forecasted to record lucrative growth on account of large presence of geriatric population base that is susceptible to valvular diseases. These drugs are effective against a number of valvular diseases and are preferred by patients and doctors as an effective treatment option. Growing inclination towards a sedentary lifestyle supported by proliferating habit of binge eating, specifically among millennials, could give rise to a series of valvular diseases, consequently driving the demand for atrial fibrillation medications.

According to the American Heart Association 2.7 million Americans are living with atrial fibrillation. Other sources predict that as the global population continues to age, the number will increase to 6 to 12 million in the USA by 2050 and 17.9 million in Europe by 2060. Though the reasons for the prevalence of atrial fibrillation remain elusive, according to the World Heart Federation atrial fibrillation utilizes significant health resources globally.

Get sample copy of this research report @

Studies to evaluate the use of direct-acting oral anticoagulants have been increasing in nursing home residents ever since their introduction. Nursing homes necessarily house the greatest number of residents at the risk of atrial fibrillation. Therefore the rise of anticoagulant use among nursing home patients is a positive indicator for the increased scope of the atrial fibrillation drugs industry.

Still, the atrial fibrillation drugs market in developed nations like the U.S. is arguably one of the largest in the world due to the fact that patients in developed countries have better access to healthcare services and are therefore not only aware of conditions like atrial fibrillation but also undergo timely diagnosis and medication which makes the atrial fibrillation drugs industry much more expansive in such countries. For instance, the U.S. atrial fibrillation drugs market is expected to witness a CAGR of 2.4% over 2019-2025 due to rising venture capital investments by manufacturing firms, increasing geriatric population and growing adoption of new pharmaceutical drugs.

With global awareness about atrial fibrillation and the importance of preventing atrial fibrillation with medication on the rise, it is expected that the trend witnessed in developed countries will be extended to developing countries as well. The would consequently expand the growth scope for atrial fibrillation drugs market that is slated to amass substantial proceeds over 2019-2025.

Prominent industry players like Pfizer, Johnson & Johnson, Bayer AG, Sanofi, Bristol-Myers Squibb, Boehringer Ingelheim, AstraZeneca, and Daiichi Sankyo are focusing on developing new solutions with enhanced functionality to enhance patient’s treatment outcomes. Companies are collaborating with other firms to develop new therapies as well as spread health awareness. 

Request for a Customization of this research report @

Partial Chapter of the Table of Content

Chapter 6. Atrial Fibrillation Drugs Market, By Application

6.1. Global market share, by application, 2018 & 2025

6.2. Heart Rhythm Control

6.2.1. Market size, by region, 2014 – 2025 (USD Million)

6.3. Heart Rate Control

6.3.1. Market size, by region, 2014 – 2025 (USD Million)

Chapter 7. Atrial Fibrillation Drugs Market, By Route of Administration

7.1. Global market share, by route of administration, 2018 & 2025

7.2. Oral

7.2.1. Market size, by region, 2014 – 2025 (USD Million)

7.3. Injectable

7.3.1. Market size, by region, 2014 – 2025 (USD Million)

Chapter 8. Atrial fibrillation Drugs Market, By End-use

8.1. Global market share by end-use, 2018 & 2025

8.2. Hospitals

8.2.1. Market size, by region, 2014 – 2025 (USD Million)

8.3. Cardiac Centers

8.3.1. Market size, by region, 2014 – 2025 (USD Million)

8.4. Ambulatory Surgical Centers

8.4.1. Market size, by region, 2014 – 2025 (USD Million)

8.5. Others

8.5.1. Market size, by region, 2014 – 2025 (USD Million)

Browse complete Table of Contents (ToC) of this research report @